Nabriva Therapeutics presents data on lefamulin at ECCMID 2015
27 April 2015 | By Victoria White
Three posters on the Extended Spectrum Pleuromutilins (ESP) Programme and one poster on lefamulin were presented at ECCMID 2015...
List view / Grid view
News
New innovations in upstream and downstream bioprocessing on display at Interphex 2015
Thermo Fisher Scientific Inc., the world leader in serving science, is unveiling new bioprocessing technologies to address the evolving needs for enhancing the efficiency and productivity of global biopharmaceutical manufacturers. These advancements include single-use systems, purification, cell culture media, analytical systems, adherent cell culture, customized fluid transfer systems and laboratory…
ESCMID honours Médecins Sans Frontières with special excellence award for outstanding achievement
27 April 2015 | By
The European Society of Clinical Microbiology and Infectious Disease (ESCMID) has issued a special excellence award to Médecins Sans Frontières...
Professional medical writing strengthens research reporting, shows Oxford PharmaGenesis
27 April 2015 | By Victoria White
Professional medical writing improves the quality of clinical trial reporting, demonstrates a study presented at the 11th Annual Meeting of the ISMPP...
Sartorius Stedim Biotech acquires UK-based CRO, BioOutsource
Sartorius Stedim Biotech (SSB), a leading international supplier for the biopharmaceutical industries, today acquired the Scottish company BioOutsource Ltd.
BMS receives positive CHMP opinion of new ORENCIA ClickJect Pre-Filled Pen for use in adult patients with moderate to severe active rheumatoid arthritis
27 April 2015 | By Victoria White
CHMP has adopted a positive opinion, approving BMS’ ClickJect Pre-Filled Pen for use in adult patients with moderate to severe active rheumatoid arthritis...
AbbVie presents preliminary safety and efficacy data from its Phase 3b RUBY-I study
27 April 2015 | By Victoria White
AbbVie announced new, preliminary safety and efficacy data from the first cohort of its ongoing, Phase 3b RUBY-I study at ILC 2015...
FDA approves Cyramza for use with FOLFIRI in second-line treatment of metastatic colorectal cancer
27 April 2015 | By Victoria White
The FDA has approved Cyramza in combination with FOLFIRI chemotherapy for the treatment of patients with metastatic colorectal cancer (mCRC)...
Primary endpoints met in ALLY-1 trial evaluating a daclatasvir-based regimen in HCV
27 April 2015 | By Victoria White
Primary endpoints were successfully met in a Phase III clinical trial evaluating a 12-week daclatasvir-based regimen for the treatment of patients with HCV...
ELPA launches new digital guide ‘C: My Journey’ for people diagnosed with hepatitis C
24 April 2015 | By Victoria White
ELPA has launched ‘C: My Journey’, an online resource where people diagnosed with HCV can go to find out more about the condition and how to get support...
Malaria vaccine candidate RTS,S has demonstrated efficacy over 3-4 years of follow-up
24 April 2015 | By Victoria White
Phase III trial results of the RTS,S vaccine candidate show that it helped protect children from clinical malaria for at least 3 years after vaccination...
First patient enrolled in Phase II study evaluating laquinimod for primary progressive MS
24 April 2015 | By Victoria White
The first patient has been enrolled in a Phase II study evaluating laquinimod, an investigational, oral, immune modulator, for the treatment of PPMS...
Innate Pharma and Astrazeneca announce co-development and commercialisation collaboration for IPH2201
24 April 2015 | By Victoria White
Innate Pharma has signed a co-development and commercialisation agreement with AstraZeneca to accelerate and broaden the development of IPH2201...
Bristol-Myers Squibb receives positive opinion from CHMP for Opdivo for advanced melanoma
24 April 2015 | By Victoria White
The CHMP has adopted a positive opinion recommending that Bristol-Myers Squibb’s Opdivo be granted approval for use in patients with advanced melanoma...
Regeneron led the way for mid-cap biotech research and development spending in 2014
24 April 2015 | By Victoria White
The combined spend on research and development (R&D) for the peer group of 35 mid-cap biotech companies increased by nearly $2 billion to reach a total of $9.7 billion in 2014, primarily thanks to top spenders Regeneron and Vertex, says leading research and consulting firm GlobalData.
